Adicet Bio

Adicet Bio, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts. The company specializes in the discovery and development of allogeneic gamma delta T cell therapies aimed at treating cancer and autoimmune diseases. Adicet Bio focuses on engineering gamma delta 1 T cells with Chimeric Antigen Receptors (CARs) to improve tumor targeting and enhance immune responses. The company's lead product candidate, ADI-001, is currently in Phase 1 clinical trials for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma and several autoimmune conditions. Adicet is also developing ADI-002, which targets various solid tumors, and ADI-925, aimed at tumor stress ligands, both in preclinical stages. Their innovative approach allows for off-the-shelf therapies, making treatments readily available to patients without the need for personalized cell harvesting. Adicet Bio collaborates with Regeneron Pharmaceuticals to advance its gamma delta T cell platform, further enhancing its capabilities in immune cell therapeutics.